Pfizer CEO Albert Bourla said there are "opportunities that probably outweigh the risks" of the Trump administration's ...

Pfizer CEO has met with the new administration and believes Trump and RFK Jr. are going to be net positives for the health sector.

Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.

CEO Albert Bourla told investors Tuesday morning that he is “cautiously optimistic” about working with Robert F. Kennedy Jr., ...

The pharma executive is optimistic about the new US administration but is also realistic about the risks that come with "radical change." ...

In an interview on CNBC’s Mad Money, Dr. Albert Bourla said Pfizer (PFE) is focusing on business development to create shareholder value. “We ...

Bourla outlined 2025 priorities, which include improving R&D productivity, achieving margin expansion, and maintaining commercial excellence. He highlighted expectations for nine Phase 3 readouts, 13 ...

Q4 2024 Earnings Conference Call February 4, 2025 10:30 AM ETCompany ParticipantsFrancesca DeMartino - Senior Vice President, ...

Few CEOs know the double-edged nature of dealing with US President Donald Trump as viscerally as Pfizer’s Albert Bourla. In his first term, Trump championed the $18 billion Operation Warp Speed ...

With just one asset in weight loss moving through the clinic, Pfizer targets the space for potential dealmaking, as well as ...

Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as ...